RBC Capital Sticks to Their Hold Rating for Regeneron (REGN)
In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Regeneron, with a price target of $745.00.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Abrahams covers the Healthcare sector, focusing on stocks such as Incyte, Regeneron, and Biogen. According to TipRanks, Abrahams has an average return of 6.2% and a 48.71% success rate on recommended stocks.
In addition to RBC Capital, Regeneron also received a Hold from Scotiabank’s Louise Chen in a report issued on February 2. However, on February 8, Guggenheim maintained a Buy rating on Regeneron (NASDAQ: REGN).
Based on Regeneron’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.88 billion and a net profit of $844.6 million. In comparison, last year the company earned a revenue of $3.79 billion and had a net profit of $917.7 million
Read More on REGN:
Disclaimer & DisclosureReport an Issue
- Regeneron price target raised to $975 from $865 at Guggenheim
- Regeneron Targets Early Myeloma: New Phase 3 Trial Pits Linvoseltamab Against Daratumumab
- Regeneron’s REGN9533 Trial Completion Signals Quiet but Important Progress in Clot-Blocking Drugs
- Regeneron’s Expanding AI Use Raises Data Privacy, Regulatory and Market Risks
- Regeneron Broadens Women’s Health Pipeline With New Phase 2 FHA Trial
